Jochen Buechner
0000-0001-5848-4501
Oslo University Hospital
94 papers found
Refreshing results…
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
Correction: Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens
Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Therapy-induced Deletion in 11q23 Leading to Fusion ofKMT2AWithARHGEF12and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3
Hematopoietic stem cell transplantation positively affects the natural history of cancer in Nijmegen breakage syndrome
Second-Tier Next Generation Sequencing Integrated in Nationwide Newborn Screening Provides Rapid Molecular Diagnostics of Severe Combined Immunodeficiency
ABO incompatibile graft management in pediatric transplantation.
Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).
Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study.
Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
Tisagenlecleucel For Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Preliminary Report of B2001X Focusing On Prior Exposure To Blinatumomab and Inotuzumab
TBI Or Chemotherapy Based Conditioning For Children And Adolescents With ALL: A Prospective Randomized Multicenter-Study “Forum” on behalf of the AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP
BIANCA: Phase 2, Single-Arm, Global Trial To Determine Efficacy And Safety Of Tisagenlecleucel In Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Missing publications? Search for publications with a matching author name.